Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

To take part in the MaesTTRo study, you would need to be at least 18 years old and have a confirmed diagnosis of transthyretin amyloidosis (ATTR). It's also important that you are willing and able to understand and sign a consent form, and fill out some health questionnaires on a regular basis.

There are some reasons why you wouldn't be able to join. For example, if you are currently taking part in another clinical trial that is testing a new treatment for ATTR. Also, if you have other types of amyloidosis, like AL or AA amyloidosis, or if you have ATTR but do not have any symptoms yet, you wouldn't be eligible for this particular study.

If you decide to join the MaesTTRo study, you won't need any extra clinic visits or procedures. All the information will be collected during your usual appointments with your doctor. You'll be asked to fill out some electronic health questionnaires about your well-being when you first join and then every six months during your routine clinic visits. These questionnaires help researchers understand how you're feeling and how your condition affects you.

The study will also gather information about your health and treatments from your medical records, just as your doctor usually collects it. There are no new medications to take as part of this study. The total time you'd be involved in the study could range from at least three years, up to seven years, depending on when you join.